CBPD‑409 is an experimental, oral medicine designed to remove two helper proteins, CBP and p300, that prostate tumors use to turn cancer‑driving genes on. These proteins partner with the androgen receptor (AR), the key signal that fuels most prostate cancers, especially in the advanced, treatment‑resistant setting. By tagging CBP and p300 for destruction, a strategy […]
LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! This week’s photo features me and my better half! (Mine is the hand underneath.) We celebrated our anniversary, and here I am, still full from dinner, finishing up the newsletter! This week, too, we have some exciting updates on […]
The ARASENS trial, a large phase 3 study, investigated the impact of adding darolutamide, a novel androgen receptor inhibitor, to the standard treatment of androgen-deprivation therapy (ADT) and docetaxel chemotherapy in patients with metastatic hormone-sensitive prostate cancer (mHSPC). A recent subgroup analysis focused on whether the benefits of this combination extend across age groups. In […]
AB-3028 represents a next-generation approach to solid-tumor CAR T therapy tailored to the unique challenges of metastatic castration-resistant prostate cancer. CAR T cells, transformative in hematologic malignancies, have struggled in solid tumors due to heterogeneous antigen expression, on-target off-tumor risks, suppressive cytokines like TGF-β, and chronic stimulation that drives exhaustion. AB-3028 was engineered to counter […]
A new study shows, published on Nature, that a little-known protein called PTGES3 helps prostate cancer cells keep using male hormone signals to grow, even when treatments are trying to shut those signals down. Blocking this helper protein cut off the cancer’s fuel supply in lab tests and slowed tumors in mice, pointing to a […]
GenSci143 (aka GenSci-143) is a bispecific antibody-drug conjugate under development for metastatic castration-resistant prostate cancer (mCRPC) and other solid tumors. The construct targets B7-H3 (CD276) and PSMA simultaneously with a bispecific antibody, coupled via a stable, cleavable linker to a topoisomerase I inhibitor payload, aiming to improve tumor cell killing and bystander effects across heterogeneous […]
A new trial will test whether nightly low‑dose naltrexone (3 mg) reduces fatigue in men with prostate cancer receiving androgen‑deprivation therapy (ADT), while concurrently profiling mitochondrial, inflammatory, and oxidative stress pathways that may drive cancer‑related fatigue in this setting. The single‑arm University of Arkansas study plans to enroll 60 men over 30 months, using FACIT‑F […]
LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! Get ready, folks! I knew I shouldn’t have used up all the best articles last week! This week seems rather poor in comparison, but fear not…the research goes on! Stay strong and fight on! As usual, we also have […]
City of Hope Medical Center, in collaboration with the National Cancer Institute, is initiating a randomized phase 1 study in metastatic castration‑resistant prostate cancer (mCRPC) that compares lutetium Lu 177 vipivotide tetraxetan (177Lu‑PSMA‑617 or Pluvicto) alone versus the same radioligand combined with sipuleucel‑T, with the primary goal of quantifying the induced anti‑tumor immune response alongside […]
A novel dual payload peptide drug conjugate technology, known as the pre|CISION® platform, represents an advance in oncology by delivering two complementary anticancer therapies from a single molecule. This approach leverages the fibroblast activation protein (FAP), which is selectively present in the tumor microenvironment, especially in advanced prostate cancer such as castration-resistant prostate cancer (CRPC). […]